<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="709">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>4/10/2005</approvaldate>
  <actrnumber>ACTRN12605000577617</actrnumber>
  <trial_identification>
    <studytitle>Mirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: A double-blind, randomised, placebo controlled trial</studytitle>
    <scientifictitle>Mirtazapine add-on therapy in the treatment of schizophrenia with atypical neuroleptics: A double-blind, randomised, placebo controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Schizophrenia</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Schizophrenia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>6-week trial of mirtazapine (30 mg/day) in addition to antipsychotic treatment as usual.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Significant difference by week 6 between mirtazapine treated and placebo treated groups using the Positive and negative symptoms scale (PANSS).</outcome>
      <timepoint>Measurements at baseline and weeks 1, 2, 4 and 6.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical global impression (CGI)</outcome>
      <timepoint>Measured at baseline, and at weeks 1, 2, 4 and 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton Depression rating scale (HAMD)</outcome>
      <timepoint>Measured at baseline, and at weeks 1, 2, 4 and 6.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Simpson Angus Scale</outcome>
      <timepoint>Measured at baseline, and at weeks 1, 2, 4 and 6.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of schizophrenia confirmed by the Mini International Neuropsychiatric Interview (MINI).Currently being treated with an atypical antipsychotic. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with significant medical illnesses and patients on any other psychotropic agents except benzodiazepines, patients who have a history of any other major psychiatric disorder, and patients meeting criteria for substance abuse or who regularly consume over 3 alcoholic drinks daily, pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>placebo and mirtazapine tablets identical in appearance and in a coded container</concealment>
    <sequence>randomisation log generated by coin toss</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Melbourne</primarysponsorname>
    <primarysponsoraddress>Parkville 
Victoria 3010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Organon</fundingname>
      <fundingaddress>Schering-Plough Pty Limited
Level 4, 66 Waterloo Road
North Ryde NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Adelaide Hospital</sponsorname>
      <sponsoraddress>Glenside Hospital
226 Fullerton Rd
Eastwood, Adelaide  5063</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Glenside Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Northern Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Seetal Dodd</name>
      <address>Swanston Centre
Barwon Health
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 52267666</phone>
      <fax>+61 3 52465165</fax>
      <email>seetald@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Seetal Dodd</name>
      <address>Swanston Centre
Barwon Health
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 52267666</phone>
      <fax>+61 3 52465165</fax>
      <email>seetald@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>